These facts suggest that the expression of CD39 most likely defines highly exhausted CD8+ T cells in ESCC which are unable to exert anti-tumor effects, and CD39-expressing CD8+ T cells could as a new molecular marker for diagnosis and prognosis of ESCC. This evidence concerns the gene CD8A and neoplasm.